The traditional Chinese medicine sector has changed again, and Tailong Pharmaceutical, Teyi Pharmaceutical, etc. are up and down!

【Pharmaceutical Network Pharmaceutical Stock Market】News on November 29, the traditional Chinese medicine sector has changed again, individual stocks, as of 10:00 on the 29th, Tailong Pharmaceutical, Teyi Pharmaceutical, Qianhong Pharmaceutical, Jingfeng Pharmaceutical, etc.
rose to the limit, KunYao Group, Miracle Pharmaceutical, Buchang Pharmaceutical, Panlong Pharmaceutical, Wohua Pharmaceutical, Zixin Pharmaceutical, etc
.
have followed suit.
As of 10:00 on the 29th, Tailong Pharmaceutical rose to the limit, with a quotation of 8.
88 yuan, a turnover of 692 million, a turnover rate of 13.
88%, and a loss in price-earnings (TTM
).
Tailong Pharmaceutical has experienced many ups and downs in recent days, and the company also announced that after verification, the company did not find any media reports or market rumors that may have a significant impact on the trading price of the company's shares, and did not involve the concept of market hot spots
.
In view of the large fluctuation range of the company's stock price, the company's current price-earnings ratio is significantly higher than the average valuation level of the same industry, the company especially reminds investors to pay attention to the risks of secondary market transactions, make rational decisions, and invest
prudently.
As of 10:00 on the 29th, Teyi Pharmaceutical also rose to the limit, with a quotation of 32.
88 yuan, a turnover of 682 million, a turnover rate of 13.
64%, and a price-to-earnings (TTM) of 61.
37
.
Teyi Pharmaceutical is also a hot stock in traditional Chinese medicine, and has repeatedly walked out of the limit
since October.
Among them, the company concentrated on disclosing the relevant information of the company's core product cough suppressant tablets on November 17, and gave the vision
of "annual sales of 2.
4 billion tablets".
The news was transmitted to the capital market, on November 18~19, the stock rose by 9.
98% and 10.
02%, respectively, and continued the upward trend on November 22, reaching 31.
8 yuan / share intraday, and closed at 31.
14 yuan / share
on the same day.
According to the annual report, Teyi Pharmaceutical takes the sales of proprietary Chinese medicines as its main source of
income.
In recent years, the company has explored the way of pharmaceutical health consumption, and transformed into medical beauty
in 2021.
As of 10:00 on the 29th, Qianhong Pharmaceutical rose to the limit, with a quotation of 6.
42 yuan, a turnover of 213 million, a turnover rate of 3.
71%, and a price-to-earnings (TTM) of 31.
66
.
On November 15 this year, Changzhou Bureau of Industry and Information Technology issued the "Jiangsu Province 2022 Specialized and Special New Small and Medium-sized Enterprises and 2019 Specialized and Special New Enterprise Review Approved Enterprise List Publicity", Qianhong Pharmaceutical was recognized as a provincial specialized and special new enterprise
for the first time.
As of 10:00 on the 29th, Jingfeng Pharmaceutical rose to the limit, the quotation was 3.
91 yuan, the turnover was 207 million, the turnover rate was 6.
84%, and the price-earnings (TTM) loss
.
According to the data, the company's main business covers cardiovascular and cerebrovascular, tumor, orthopedics, pediatrics, gynecology and other major diseases, and the main products are injections
.
On the news, Jingfeng Pharmaceutical recently issued an announcement that Shanghai Jingfeng Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of the company, intends to sell its real estate located in Lane 868, Puming Road, Pudong New Area, Shanghai, to Yue Hongwei, a natural person, for 120 million yuan, equivalent to a unit price of 144,700 yuan / square meter
.
From the perspective of the industry background, since the National Day, the traditional Chinese medicine sector has risen many times, mainly because of favorable policies to support industrial development
.
For example, on November 11, the State Food and Drug Administration issued the Special Provisions on the Registration and Administration of Traditional Chinese Medicines (Draft for Comments), which revised and improved
on the basis of the Supplementary Provisions on the Registration and Administration of Traditional Chinese Medicines issued in 2008.
The industry expects that the Draft will play a strong role in promoting the development of innovative Chinese medicine drugs
.
On the same day, the National Health Commission issued a relevant notice, which mentioned that it attaches importance to giving full play to the unique advantages of traditional Chinese medicine and making a reserve
of effective traditional Chinese medicine prescription drugs.
In addition, the current 2022 medical insurance negotiations are imminent, it is reported that this round of negotiations has 8 innovative Chinese medicine drugs are expected to be included in the national medical insurance catalog, looking back at the previous medical insurance negotiations, the pass rate of traditional Chinese medicines in negotiations is significantly higher than that of western medicines, and the price reduction is relatively mild, and the average price reduction is lower than that of western medicines
.
This will be conducive to the development of
innovative Chinese medicine.
Overall, the industry generally believes that traditional Chinese medicine has the attributes of consumer goods and health care products, and with the aging of the population and consumption upgrading, as well as favorable policy support, the sector has a long-term growth logic
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.